Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study

Background and Objectives: There is a lack of data regarding hormonal metabolic abnormalities resulting from the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), a commonly used chemotherapy in diffuse large B-cell lymphoma (DLBCL). This study aimed to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Manosroi, Worapaka, Chirayucharoensak, Jiraporn, Chai-adisaksopha, Chatree, Phinyo, Phichayut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230452/
https://www.ncbi.nlm.nih.gov/pubmed/35743974
http://dx.doi.org/10.3390/medicina58060710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230452/
https://www.ncbi.nlm.nih.gov/pubmed/35743974
http://dx.doi.org/10.3390/medicina58060710

Ejemplares similares